United Therapeutics Corporation and TG Therapeutics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, United Therapeutics Corporation and TG Therapeutics, Inc. have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.

United Therapeutics: A Steady Climb

United Therapeutics has consistently increased its SG&A spending, peaking in 2022 with a 25% rise from 2014. This steady growth reflects a robust investment in administrative capabilities and market expansion.

TG Therapeutics: A Volatile Journey

Conversely, TG Therapeutics has experienced a more volatile SG&A trajectory. Notably, their expenses surged by over 500% from 2014 to 2021, indicating aggressive market entry strategies and potential restructuring efforts.

Conclusion

These spending patterns highlight the diverse strategies employed by biotech firms to navigate market challenges and opportunities.